BioCentury | Apr 15, 2013
Company News

TheraTech, Schwarz Pharma deal

...also retains manufacturing rights and certain co-marketing rights. TheraTech Inc. (THRT), Salt Lake City, Calif. Schwarz Pharma AG...
BioCentury | Jan 28, 2013
Clinical News

Toviaz fesoterodine: Phase IV data

...be increased to 8 mg once daily. The pharma has worldwide rights to Toviaz from Schwarz Pharma AG...
BioCentury | Jan 7, 2013
Finance

Highlights of weekly biotech stock moves

...and moderate to severe idiopathic restless leg syndrome (RLS). Otsuka has exclusive, Japanese rights from Schwarz Pharma AG...
BioCentury | Dec 27, 2012
Company News

Japan approves four products

...the transdermal patch of a once-daily dopamine D2 receptor agonist under a 2002 deal with Schwarz Pharma AG...
BioCentury | Aug 13, 2012
Clinical News

Toviaz fesoterodine: Phase IV data

...and EU to treat symptoms of OAB. The pharma has worldwide rights to Toviaz from Schwarz Pharma AG...
BioCentury | Jun 11, 2012
Company News

Pfizer sales and marketing update

...$2.43 per tablet for each dose. Pfizer has worldwide rights to the anti-muscarinic agent from Schwarz Pharma AG...
BioCentury | Mar 8, 2010
Strategy

Merck's Chemical Test

...Group plc , at the time Europe's largest entrepreneurial biotech company. In 2006, UCB added Schwarz Pharma AG...
BioCentury | Jun 8, 2009
Company News

UCB, Pfizer sales and marketing update

...bladder (OAB). The price is undisclosed. Pfizer has worldwide rights to the anti-muscarinic agent from Schwarz Pharma AG...
BioCentury | Dec 8, 2008
Company News

ViroPharma, Schwarz Pharma deal

...trial of the molecule to treat viral meningitis in adults. ViroPharma Inc. (VPHM), Malvern, Penn. Schwarz Pharma AG...
BioCentury | Nov 3, 2008
Clinical News

Toviaz fesoterodine regulatory update

...is approved in the EU for the indication. Pfizer has worldwide rights to Toviaz from Schwarz Pharma AG...
Items per page:
1 - 10 of 183
BioCentury | Apr 15, 2013
Company News

TheraTech, Schwarz Pharma deal

...also retains manufacturing rights and certain co-marketing rights. TheraTech Inc. (THRT), Salt Lake City, Calif. Schwarz Pharma AG...
BioCentury | Jan 28, 2013
Clinical News

Toviaz fesoterodine: Phase IV data

...be increased to 8 mg once daily. The pharma has worldwide rights to Toviaz from Schwarz Pharma AG...
BioCentury | Jan 7, 2013
Finance

Highlights of weekly biotech stock moves

...and moderate to severe idiopathic restless leg syndrome (RLS). Otsuka has exclusive, Japanese rights from Schwarz Pharma AG...
BioCentury | Dec 27, 2012
Company News

Japan approves four products

...the transdermal patch of a once-daily dopamine D2 receptor agonist under a 2002 deal with Schwarz Pharma AG...
BioCentury | Aug 13, 2012
Clinical News

Toviaz fesoterodine: Phase IV data

...and EU to treat symptoms of OAB. The pharma has worldwide rights to Toviaz from Schwarz Pharma AG...
BioCentury | Jun 11, 2012
Company News

Pfizer sales and marketing update

...$2.43 per tablet for each dose. Pfizer has worldwide rights to the anti-muscarinic agent from Schwarz Pharma AG...
BioCentury | Mar 8, 2010
Strategy

Merck's Chemical Test

...Group plc , at the time Europe's largest entrepreneurial biotech company. In 2006, UCB added Schwarz Pharma AG...
BioCentury | Jun 8, 2009
Company News

UCB, Pfizer sales and marketing update

...bladder (OAB). The price is undisclosed. Pfizer has worldwide rights to the anti-muscarinic agent from Schwarz Pharma AG...
BioCentury | Dec 8, 2008
Company News

ViroPharma, Schwarz Pharma deal

...trial of the molecule to treat viral meningitis in adults. ViroPharma Inc. (VPHM), Malvern, Penn. Schwarz Pharma AG...
BioCentury | Nov 3, 2008
Clinical News

Toviaz fesoterodine regulatory update

...is approved in the EU for the indication. Pfizer has worldwide rights to Toviaz from Schwarz Pharma AG...
Items per page:
1 - 10 of 183